Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $84.98, with a market capitalisation of $9.01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $31.00 to $85.01. This page covers its latest market performance, valuation, price trends and company information.
$9.01B | |
$84.96 | |
$85.01 | |
$10.63 | |
$84.84 | |
3.73M | |
-- | |
-- | |
$85.01 | |
$31.00 | |
-- | |
-- |
Crinetics Pharmaceuticals, Inc. (CRNX) is trading at $-- in pre-market trading as of 2026-08-31 23:50:00, -- from the previous close of $84.84
Pre-market trading shows how investors are pricing CRNX before the regular session opens. The current pre-market price is -- the previous close, indicating -- early trading sentiment.
Over the past seven days, Crinetics Pharmaceuticals, Inc. (CRNX) moved from $84.85 to $84.98, representing a gain of 0.15% ($0.13).
The stock traded between $84.69 and $85.01 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 2.15 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 99.9%
CRNX is currently trading at $84.98, placing it 99.9% of the way from its 52-week low of $31.00 to its 52-week high of $85.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 594 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Crinetics Pharmaceuticals, Inc. (CRNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.